TFFP vs. SONN, PTIX, ADXS, CING, FWBI, HOTH, GNPX, XBIO, SNPX, and KTRA
Should you be buying TFF Pharmaceuticals stock or one of its competitors? The main competitors of TFF Pharmaceuticals include Sonnet BioTherapeutics (SONN), Protagenic Therapeutics (PTIX), Ayala Pharmaceuticals (ADXS), Cingulate (CING), First Wave BioPharma (FWBI), Hoth Therapeutics (HOTH), Genprex (GNPX), Xenetic Biosciences (XBIO), Synaptogenix (SNPX), and Kintara Therapeutics (KTRA). These companies are all part of the "pharmaceutical preparations" industry.
Sonnet BioTherapeutics (NASDAQ:SONN) and TFF Pharmaceuticals (NASDAQ:TFFP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk, earnings and community ranking.
Sonnet BioTherapeutics presently has a consensus target price of $30.00, indicating a potential upside of 1,664.71%. TFF Pharmaceuticals has a consensus target price of $72.00, indicating a potential upside of 3,944.94%. Given Sonnet BioTherapeutics' higher possible upside, analysts plainly believe TFF Pharmaceuticals is more favorable than Sonnet BioTherapeutics.
Sonnet BioTherapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, TFF Pharmaceuticals has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.
TFF Pharmaceuticals has a net margin of -2,897.95% compared to TFF Pharmaceuticals' net margin of -11,187.19%. Sonnet BioTherapeutics' return on equity of -163.14% beat TFF Pharmaceuticals' return on equity.
In the previous week, Sonnet BioTherapeutics and Sonnet BioTherapeutics both had 2 articles in the media. TFF Pharmaceuticals' average media sentiment score of 0.85 beat Sonnet BioTherapeutics' score of 0.44 indicating that Sonnet BioTherapeutics is being referred to more favorably in the media.
Sonnet BioTherapeutics has higher earnings, but lower revenue than TFF Pharmaceuticals.
9.5% of Sonnet BioTherapeutics shares are held by institutional investors. Comparatively, 15.3% of TFF Pharmaceuticals shares are held by institutional investors. 2.0% of Sonnet BioTherapeutics shares are held by insiders. Comparatively, 4.5% of TFF Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
TFF Pharmaceuticals received 50 more outperform votes than Sonnet BioTherapeutics when rated by MarketBeat users. However, 80.95% of users gave Sonnet BioTherapeutics an outperform vote while only 67.68% of users gave TFF Pharmaceuticals an outperform vote.
Summary
TFF Pharmaceuticals beats Sonnet BioTherapeutics on 9 of the 14 factors compared between the two stocks.
Get TFF Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TFFP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TFFP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TFF Pharmaceuticals Competitors List
Related Companies and Tools
